Clicky

IDEAYA Biosciences, Inc.(IDYA) News

Date Title
Mar 12 IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
Mar 4 IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
Feb 23 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 15 IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last?
Dec 5 IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event
Dec 4 IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer
Dec 3 IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023
Sep 11 IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors
Aug 16 IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma
Aug 10 IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Lags Revenue Estimates
Aug 10 IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
Apr 29 Institutional investors are IDEAYA Biosciences, Inc.'s (NASDAQ:IDYA) biggest bettors and were rewarded after last week's US$297m market cap gain
Apr 28 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apr 27 IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Apr 25 Strength Seen in IDEAYA Biosciences, Inc. (IDYA): Can Its 35.7% Jump Turn into More Strength?
Apr 25 IDEAYA Announces Pricing of Public Offering
Apr 24 IDEAYA Announces Proposed Public Offering of Common Stock
Apr 24 IDEAYA Biosciences Touts Encouraging Data From Combo Therapy For Rare Eye Cancer Impacting Around 14,000 In US and Europe